Bellerophon Therapeutics, Inc.BLPH
Market cap
$146.79K
P/E ratio
| Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
| Net loss | - | - | - | - | - | -25 | -18 | -20 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 3 | 3 | 3 | 2 | 2 | 1 | 1 |
| Fair Value Adjustment of Warrants | - | 1 | 30 | -25 | -3 | 0 | -1 | -0 |
| Financing expense | - | - | - | - | - | 0 | - | - |
| Prepaid expenses and other current assets | 4 | 1 | -3 | -3 | -0 | 0 | 0 | -0 |
| Accounts payable, accrued research and development, accrued expenses and other liabilities | -1 | -2 | 1 | 0 | -0 | 2 | -5 | 1 |
| Net cash used in operating activities | - | - | -16 | -15 | -13 | -20 | -23 | -18 |
| Proceeds from Warrant Exercises | - | - | 2 | 0 | - | 3 | - | - |
| Payment of expenses related to the ATM sale agreement | - | - | - | - | - | 0 | - | - |
| Public Offering | - | - | - | - | - | 26 | - | - |
| Direct Offering | - | - | - | - | - | 28 | - | - |
| Proceeds From Issuance Of Common Stock, Net | - | - | - | - | 6 | - | - | - |
| Tax withholding payments for stock compensation | - | 0 | - | - | 0 | - | - | 0 |
| Net cash (used in) provided by financing activities | - | - | 28 | 0 | 6 | 58 | - | -0 |
| Net change in cash, cash equivalents and restricted cash | - | - | - | -12 | -7 | 38 | -23 | -18 |